P F
Mar 1, 2026

Provider Notification: Apretude® (cabotegravir) Benefit Change

Effective February 26, 2026 Apretude® will transition from the medical benefit to the pharmacy (Rx) benefit. This change allows Apretude® to be filled and dispensed through a retail or specialty pharmacy, rather than billed under the medical benefit.

What this means for providers and patients:

  • Improved access: Pharmacy dispensing streamlines the process and reduces administrative burden.
  • Lower overall cost: Coverage under the Rx benefit is expected to improve affordability for members.
  • Simplified billing: Claims will be processed through the pharmacy benefit rather than medical claims.
  • No change to clinical use: Indications, dosing schedule, and administration of Apretude® remain unchanged.